Cargando…

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults

OBJECTIVES: In Canada, incidences of herpes zoster (HZ) and postherpetic neuralgia (PHN) are increasing, posing a significant burden on the healthcare system. This study aimed to determine the public health impact and cost effectiveness of an adjuvanted recombinant zoster vaccine (RZV) compared to n...

Descripción completa

Detalles Bibliográficos
Autores principales:	McGirr, Ashleigh, Van Oorschot, Desiree, Widenmaier, Robyn, Stokes, Michael, Ganz, Michael L., Jung, Hyosung, Varghese, Lijoy, Curran, Desmond
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748891/ https://www.ncbi.nlm.nih.gov/pubmed/31250218 http://dx.doi.org/10.1007/s40258-019-00491-6

Ejemplares similares

Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old
por: Van Oorschot, Desirée, et al.
Publicado: (2018)

A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients’ Health-Related Quality of Life
por: Van Oorschot, Desirée, et al.
Publicado: (2022)

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
por: Shiragami, Makoto, et al.
Publicado: (2019)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
por: Curran, Desmond, et al.
Publicado: (2017)

The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis
por: Watanabe, Daisuke, et al.
Publicado: (2018)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018
por: McGirr, Ashleigh, et al.
Publicado: (2018)

The temporal impact of aging on the burden of herpes zoster
por: Varghese, Lijoy, et al.
Publicado: (2017)

Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany
por: Curran, Desmond, et al.
Publicado: (2021)

Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
por: van Oorschot, Desirée A M, et al.
Publicado: (2019)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

Estimated Public Health Impact of the Recombinant Zoster Vaccine
por: Patterson, Brandon J., et al.
Publicado: (2021)

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
por: Teng, Lida, et al.
Publicado: (2022)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
por: Giannelos, Nikolaos, et al.
Publicado: (2023)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

A systematic literature review of herpes zoster incidence worldwide
por: van Oorschot, Désirée, et al.
Publicado: (2021)

Meta-Regression of Herpes Zoster Incidence Worldwide
por: Curran, Desmond, et al.
Publicado: (2021)

1440. Meta-regression Analysis of Worldwide Herpes Zoster Incidence
por: Yawn, Barbara P, et al.
Publicado: (2021)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
por: Lee, Christa, et al.
Publicado: (2021)

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)

The impact of the COVID-19 pandemic on the incidence of herpes zoster: Nicolas Lecrenier
por: Lecrenier, N, et al.
Publicado: (2022)

2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine
por: Schmader, Kenneth E, et al.
Publicado: (2019)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

Estimation of the Underlying Burden of Pertussis in Adolescents and Adults in Southern Ontario, Canada
por: McGirr, Ashleigh A., et al.
Publicado: (2013)

The potential public health impact of Herpes Zoster vaccination in the 65 years of age cohort in Italy
por: Volpi, Antonio, et al.
Publicado: (2019)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

Assessment of the Potential Herpes Zoster and Post Herpetic Neuralgia Case Avoidance with Vaccination in the United States
por: Patterson, Brandon J, et al.
Publicado: (2017)

Healthy ageing: Herpes zoster infection and the role of zoster vaccination
por: Curran, Desmond, et al.
Publicado: (2023)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

The Value of Intermittent Venous Occlusion. Its Effect on Local Muscle Circulation as Determined by the Clearance of Radioactive Sodium (Sodium 24)
por: McGirr, E. M.
Publicado: (1952)

Cases and Observations on the Use of Strychnia in Intermittent Fevers
por: McGirr, J. E.
Publicado: (1848)

Etherization Applied to Midwifery
por: McGirr, J. E.
Publicado: (1847)

Notes of a Rattle-Snake Bite Admitted into the Ill. Gen. Hospital
por: McGirr, John E.
Publicado: (1852)

Cannot write session to /tmp/vufind_sessions/sess_7vea9ldod83foqurd175389o2i